

NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

by advance voting in accordance with section 22 of the Act (2022:121) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

The form must be received by Euroclear Sweden AB (that handles the administration of the forms on behalf of Calliditas Therapeutics) no later than Wednesday 18 May 2022.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Calliditas Therapeutics AB (publ), Reg. No. 556659-9766 at the annual general meeting on 19 May 2022. The voting right is exercised in accordance with the below marked voting options.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorized to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions to vote in advance:

- Complete the shareholder information above
- Select the preferred voting options below
- Print, sign and send the form by post to Calliditas Therapeutics AB (publ), Annual General Meeting 2022, c/o Euroclear Sweden, Box 191, SE-101 23 Stockholm, Sweden or via e-mail to GeneralMeetingService@euroclear.com (state "Calliditas Therapeutics Annual General Meeting" in

the subject line). Shareholders may also cast their advance votes electronically through BankID verification via <https://anmalan.vpc.se/EuroclearProxy/>

- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- If the shareholder votes by proxy, a power of attorney shall be enclosed with the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed to the form

Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must register its shares in its own name to vote. Instructions regarding this are included in the notice convening the meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by Euroclear Sweden AB will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The advance voting form, together with any enclosed authorization documentation, shall be received by Euroclear Sweden AB no later than **Wednesday 18 May 2022**. An advance vote can be withdrawn up to and including **Wednesday 18 May 2022**, by contacting Euroclear Sweden AB by e-mail GeneralMeetingService@euroclear.com (state "Calliditas Therapeutics Annual General Meeting" in the subject line), by post to Calliditas Therapeutics AB (publ), Annual General Meeting 2022, c/o Euroclear Sweden, Box 191, SE-101 23 Stockholm, Sweden, or by telephone, +46 8 402 91 33 (Monday-Friday, 09.00-16.00 CEST).

For complete proposals for the items on the agenda, kindly refer to the notice convening the meeting and the proposals on company's website, www.calliditas.se.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual general meeting in Calliditas Therapeutics AB (publ) on 19 May 2022

The options below comprise the proposals submitted by the Board of Directors and the nomination committee which are included in the notice convening the annual general meeting.

1. Election of a chairman at the meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
2. Election of one or two persons to attest the minutes
2.1. Patrik Sobocki Yes <input type="checkbox"/> No <input type="checkbox"/>
2.2. Karl Tobieson Yes <input type="checkbox"/> No <input type="checkbox"/>
3. Preparation and approval of the voting register Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Determination of whether the meeting was duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
7. Resolution regarding
7a. Adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
7b. Allocation of the company's profit or loss according to the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
7c. Discharge from liability for board members and the managing director
7c.1. Elmar Schnee Yes <input type="checkbox"/> No <input type="checkbox"/>
7c.2. Hilde Furberg Yes <input type="checkbox"/> No <input type="checkbox"/>
7c.3. Lennart Hansson Yes <input type="checkbox"/> No <input type="checkbox"/>
7c.4. Diane Parks Yes <input type="checkbox"/> No <input type="checkbox"/>
7c.5. Molly Henderson Yes <input type="checkbox"/> No <input type="checkbox"/>

7c.6. Renée Aguiar-Lucander (CEO) Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Determination of the number of members of the Board of Directors and the number of auditors
8.1. Number of members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8.2. Number of auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Determination of remuneration for the Board of Directors and the auditors
9.1. Remuneration for the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9.2. Remuneration for the auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
10. Election of the Board of Directors
10.1. Elmar Schnee (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.2. Hilde Furberg (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.3. Diane Parks (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.4. Molly Henderson (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.5. Henrik Stenqvist (new election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.6. Elisabeth Björk (new election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11. Election of chairman of the Board of Directors Elmar Schnee (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
12. Election of accounting firm or auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
13. Resolution on principles for appointing the nomination committee Yes <input type="checkbox"/> No <input type="checkbox"/>
14. Resolution on approval of the Board of Directors' remuneration report Yes <input type="checkbox"/> No <input type="checkbox"/>

<p>15. Resolution to authorize the Board of Directors to resolve on issue of new shares, warrants and/or convertibles</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>16. Resolutions, in order to facilitate implementation of and delivery of shares under a contemplated <i>At-the-market program</i> (the “ATM Program”), to</p>
<p>16a. Amend the articles of association</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>16b. Authorize the Board of Directors to resolve on issue of new C-shares</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>16c. Authorize the Board of Directors to resolve on purchase of C-shares</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>16d. Authorize the Board of Directors to resolve on transfer of own ordinary shares</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>17. Resolution, in order to adopt a long-term performance-based incentive program for members of the Board of Directors, on</p>
<p>17a. Adoption of a long-term performance-based incentive program for members of the Board of Directors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>17b. Issue of warrants</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>17c. Equity swap agreement with a third party</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>18. Resolution, in order to adopt a long-term incentive program for the company’s management and key personnel, on</p>
<p>18a. Adoption of a long-term incentive program for the company’s management and key personnel</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>18b. Issue of warrants</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>18c. Equity swap agreement with a third party</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued general meeting (Completed only if the shareholder has such a wish)</p> <p>Item/items (use numbering):</p>